Skip to main content
Erschienen in: Abdominal Radiology 3/2011

01.06.2011 | Invited Feature Section

Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR

verfasst von: Carlo Bartolozzi, Valentina Battaglia, Elena Bozzi

Erschienen in: Abdominal Radiology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Nowadays, the diagnosis of hepatocellular carcinoma (HCC) is increasingly demanded to imaging techniques. Anyway, imaging cirrhotic patients still remains a challenging issue, since pre-neoplastic hepatocellular lesions, as dysplastic nodules (DNs), may frequently mimic small neoplasms. Differently from other imaging modalities, magnetic resonance (MR) can give an accurate evaluation of both intracellular and vascular changes occurring during the carcinogenetic pathway from dysplasia to full malignancy. Both DNs and HCC may in fact show a large variety of signal intensities, strictly reflecting nodules’ characteristics, such as lesion architecture, grading, stromal components, as well as intracellular contents. In these last years, the introduction of dedicated contrast media has increased MR diagnostic efficacy, permitting to explore both vascular as well as the pathological changes occurring in the biliary and reticuloendothelial systems during the carcinogenetic process. MR performed with tissue specific contrast agents (hepatobiliary and reticulo-endothelial) may thus give an insight on this “gray area”, in whom significant histological changes are already present without an evident nodule arterial supply. This peculiar MR prerogative permits to give predictive information about the evolution trend in a cirrhotic parenchyma and to identify patients at high risk for developing carcinoma who would benefit from well-timed treatments.
Literatur
1.
Zurück zum Zitat Bartolozzi C, Crocetti L, Lencioni R, et al. (2007) Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 17(10):2519–2530PubMedCrossRef Bartolozzi C, Crocetti L, Lencioni R, et al. (2007) Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 17(10):2519–2530PubMedCrossRef
2.
Zurück zum Zitat MacSween RNM, Burt AD, Portmann BC, et al. (2001) Pathology of the liver, 4th edn. London: Churchill Livingstone MacSween RNM, Burt AD, Portmann BC, et al. (2001) Pathology of the liver, 4th edn. London: Churchill Livingstone
3.
Zurück zum Zitat Ahn SS, Kim MJ, Lim JS, et al. (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 225(2):459–466CrossRef Ahn SS, Kim MJ, Lim JS, et al. (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 225(2):459–466CrossRef
4.
Zurück zum Zitat Kanematsu M, et al. (2008) Magnetic resonance imaging of hepatocellular carcinoma. Oncology 75(Suppl 1):65–71PubMedCrossRef Kanematsu M, et al. (2008) Magnetic resonance imaging of hepatocellular carcinoma. Oncology 75(Suppl 1):65–71PubMedCrossRef
5.
Zurück zum Zitat Kim SH, Kim SH, Lee J, et al. (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 192:1675–1681PubMedCrossRef Kim SH, Kim SH, Lee J, et al. (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 192:1675–1681PubMedCrossRef
6.
Zurück zum Zitat Reimer P, Schneider G, Schima W, et al. (2004) Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 14:559–578PubMedCrossRef Reimer P, Schneider G, Schima W, et al. (2004) Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 14:559–578PubMedCrossRef
7.
Zurück zum Zitat Kirchin MA, Pirovano GP, Spinazzi A, et al. (1998) Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 33:798–809PubMedCrossRef Kirchin MA, Pirovano GP, Spinazzi A, et al. (1998) Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 33:798–809PubMedCrossRef
8.
Zurück zum Zitat Giovagnoni A, Paci E (1996) Liver III. Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Magn Reson Imaging Clin N Am Feb 4(1):61–72 Giovagnoni A, Paci E (1996) Liver III. Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Magn Reson Imaging Clin N Am Feb 4(1):61–72
9.
Zurück zum Zitat Spinazzi A, Lorusso V, Pirovano G, et al. (1998) Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 5(Suppl 1):S86–S89PubMedCrossRef Spinazzi A, Lorusso V, Pirovano G, et al. (1998) Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 5(Suppl 1):S86–S89PubMedCrossRef
10.
Zurück zum Zitat Hamm B, Stacks T, Muhler A, et al. (1995) Phase I Clinical Evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792PubMed Hamm B, Stacks T, Muhler A, et al. (1995) Phase I Clinical Evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792PubMed
11.
Zurück zum Zitat Raman SS, Leary C, Bluemke DA, et al. (2010) Improved characterization of focal liver lesions with liver specific gadoxetic acid disodium enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr 34(2):163–172PubMedCrossRef Raman SS, Leary C, Bluemke DA, et al. (2010) Improved characterization of focal liver lesions with liver specific gadoxetic acid disodium enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr 34(2):163–172PubMedCrossRef
12.
Zurück zum Zitat Ichicawa T, Saito K, Yoshioka N, et al. (2010) Detection and characterization of focal liver lesions : a Japanese phase III, multicenter comparison between magnetic resonance imaging and contrast enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 45(3):133–141CrossRef Ichicawa T, Saito K, Yoshioka N, et al. (2010) Detection and characterization of focal liver lesions : a Japanese phase III, multicenter comparison between magnetic resonance imaging and contrast enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 45(3):133–141CrossRef
13.
Zurück zum Zitat Seale MK, Catalano OA, Saini S, et al. (2009) Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 29(6):1725–1748PubMedCrossRef Seale MK, Catalano OA, Saini S, et al. (2009) Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 29(6):1725–1748PubMedCrossRef
14.
Zurück zum Zitat Reimer P, Balzer T (2003) Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 13:1266–1276PubMed Reimer P, Balzer T (2003) Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 13:1266–1276PubMed
15.
Zurück zum Zitat Ito K (2006) Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dynamic imaging. Eur J Radiol 58:186–199PubMedCrossRef Ito K (2006) Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dynamic imaging. Eur J Radiol 58:186–199PubMedCrossRef
16.
Zurück zum Zitat Lee JY, Kim SH, Jeon YH, et al. (2010) Ferucarbotran-enhanced magnetic resonance imaging versus gadoxetic acid-enhanced magnetic resonance imaging for the preoperative detection of hepatocellular carcinoma: initial experience. J Comput Assist Tomogr 34(1):127–134PubMedCrossRef Lee JY, Kim SH, Jeon YH, et al. (2010) Ferucarbotran-enhanced magnetic resonance imaging versus gadoxetic acid-enhanced magnetic resonance imaging for the preoperative detection of hepatocellular carcinoma: initial experience. J Comput Assist Tomogr 34(1):127–134PubMedCrossRef
17.
Zurück zum Zitat Lavelle MT, Lee VS, Rofsky NM, et al. (2001) Dynamic contrast-enhanced three-dimensional MR imaging of liver parenchyma: source images and angiographic reconstructions to define hepatic arterial anatomy. Radiology 218(2):389–394PubMed Lavelle MT, Lee VS, Rofsky NM, et al. (2001) Dynamic contrast-enhanced three-dimensional MR imaging of liver parenchyma: source images and angiographic reconstructions to define hepatic arterial anatomy. Radiology 218(2):389–394PubMed
18.
Zurück zum Zitat Mori K, Yoshioka H, Takahashi N, et al. (2005) Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late and whole triple arterial phase imaging. AJR Am J Roentgenol 184(1):63–69PubMed Mori K, Yoshioka H, Takahashi N, et al. (2005) Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late and whole triple arterial phase imaging. AJR Am J Roentgenol 184(1):63–69PubMed
19.
Zurück zum Zitat Hussain HK, Londy FJ, Francis IR, et al. (2003) Hepatic arterial phase MR imaging with automated bolus detection three dimensional fast gradient-recalled echo sequence: comparison with test bolus method. Radiology 226:558–566PubMedCrossRef Hussain HK, Londy FJ, Francis IR, et al. (2003) Hepatic arterial phase MR imaging with automated bolus detection three dimensional fast gradient-recalled echo sequence: comparison with test bolus method. Radiology 226:558–566PubMedCrossRef
20.
Zurück zum Zitat Ros PR, Freeny PC, Harms SE, et al. (1995) Hepatic MR imaging with ferumoxide: a multicentric clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196:481–488PubMed Ros PR, Freeny PC, Harms SE, et al. (1995) Hepatic MR imaging with ferumoxide: a multicentric clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196:481–488PubMed
21.
Zurück zum Zitat Roncalli M, Roz E, Coggi G, et al. (1999) The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 30(5):1174–1178PubMedCrossRef Roncalli M, Roz E, Coggi G, et al. (1999) The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 30(5):1174–1178PubMedCrossRef
22.
Zurück zum Zitat International Consensus Group for Hepatocellular Neoplasia (2009) The International Consensus Group for Hepatocellular Neoplasia Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49(2):658–664CrossRef International Consensus Group for Hepatocellular Neoplasia (2009) The International Consensus Group for Hepatocellular Neoplasia Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49(2):658–664CrossRef
23.
Zurück zum Zitat Theise ND, Park YN, Kojiro M, et al. (2002) Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 6(2):497–512PubMedCrossRef Theise ND, Park YN, Kojiro M, et al. (2002) Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 6(2):497–512PubMedCrossRef
24.
Zurück zum Zitat Shinmura R, Matsui O, Kobayashi S, et al. (2006) Cirrhotic nodules: association between MR imaging signal intensity and intranodular blood supply. Radiology 237(2):512–519CrossRef Shinmura R, Matsui O, Kobayashi S, et al. (2006) Cirrhotic nodules: association between MR imaging signal intensity and intranodular blood supply. Radiology 237(2):512–519CrossRef
25.
Zurück zum Zitat Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430PubMedCrossRef Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430PubMedCrossRef
26.
Zurück zum Zitat Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208–1236PubMedCrossRef Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208–1236PubMedCrossRef
27.
Zurück zum Zitat Kim JI, Lee JM, Choi JY, et al. (2008) The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 43(3):202–210PubMedCrossRef Kim JI, Lee JM, Choi JY, et al. (2008) The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 43(3):202–210PubMedCrossRef
28.
Zurück zum Zitat Lim JH, Choi D, Cho SK, et al. (2001) Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number. Radiology 220:669–676PubMedCrossRef Lim JH, Choi D, Cho SK, et al. (2001) Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number. Radiology 220:669–676PubMedCrossRef
29.
Zurück zum Zitat Chen RC, Lii JM, Chou CT, et al. (2008) T2-weighted and T1-weighted dynamic superparamagnetic iron oxide (ferucarbotran) enhanced MRI of hepatocellular carcinoma and hyperplastic nodules. J Formos Med Assoc 107(10):798–805PubMedCrossRef Chen RC, Lii JM, Chou CT, et al. (2008) T2-weighted and T1-weighted dynamic superparamagnetic iron oxide (ferucarbotran) enhanced MRI of hepatocellular carcinoma and hyperplastic nodules. J Formos Med Assoc 107(10):798–805PubMedCrossRef
30.
Zurück zum Zitat Mazzaferro V, Regalia E, Doci R, et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:69–693CrossRef Mazzaferro V, Regalia E, Doci R, et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:69–693CrossRef
31.
Zurück zum Zitat Llovet JM, Di Bisceglie AM, Bruix J, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711PubMedCrossRef Llovet JM, Di Bisceglie AM, Bruix J, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711PubMedCrossRef
Metadaten
Titel
Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR
verfasst von
Carlo Bartolozzi
Valentina Battaglia
Elena Bozzi
Publikationsdatum
01.06.2011
Verlag
Springer-Verlag
Erschienen in
Abdominal Radiology / Ausgabe 3/2011
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-011-9687-z

Weitere Artikel der Ausgabe 3/2011

Abdominal Radiology 3/2011 Zur Ausgabe

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.